Drug Trial Radar · NCT07090759
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
526
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Dec 1, 2026
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Fujian Akeylink Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
Conditions
- Chronic Hepatitis b
Interventions
GST-HG141Drug
GST-HG141 50 mg BID
GST-HG141 PlaceboDrug
GST-HG141 Placebo BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with serum Hepatitis B Virus (HBV) DNATime frame: Up to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shulan(Hangzhou) Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.